The MATRICS consensus cognitive battery: What We know 6 years later

American Journal of Psychiatry

Volumn 171, Issue 11, 2014, Pages 1151-1154

  Green, Michael F ^a   Harris, Josette G ^b   Nuechterlein, Keith H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 7 NICOTINIC AGONIST; BENZOIC ACID; BIOLOGICAL MARKER; NEUROLEPTIC AGENT; NICOTINIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALERTNESS; ATTENTION; BEHAVIOR CONTROL; COGNITION; COGNITIVE REMEDIATION PROGRAM; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GOVERNMENT; HEALTH BEHAVIOR; HEALTH PROGRAM; HIPPOCAMPUS; HUMAN; LEARNING; MATRICS CONSENSUS COGNITIVE BATTERY; NERVE CELL PLASTICITY; NEUROPHARMACOLOGY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; PUBLICATION; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY ANALYSIS; SMOKING; SOCIAL COGNITION; STANDARDIZATION; TEST RETEST RELIABILITY; THERAPY EFFECT; TRAINING; VALIDATION STUDY; WORKING MEMORY; BRAIN; CLINICAL TRIAL (TOPIC); CONSENSUS; CONSENSUS DEVELOPMENT; DRUG EFFECTS; METHODOLOGY; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; COGNITION; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTICENTER STUDIES AS TOPIC; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; PSYCHOMETRICS; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84910144403     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.14070936     Document Type: Review

References (23)

1. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RSE, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR: The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-213
2. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RSE, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR: The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 2008;165:214-220
3. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RSE, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR: Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 2008;165:221-228
4. Hyman SE, Fenton WS: What are the right targets for psychopharmacology? Science 2003;299:350-351
5. Marder SR, Fenton W: Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72:5-9
6. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RSE, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR: Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307
7. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK: Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39
8. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A: Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011;125:161-168
9. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012;136:25-31
10. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011;69:442-449
11. Fisher M, Holland C, Merzenich MM, Vinogradov S: Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry 2009;166:805-811
12. Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, Schlosser D, Pham L, Miskovich T, Vinogradov S: Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull (Epub ahead of print, Jan 20, 2014)
13. Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup TS: Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry 2012;73:1016-1022
14. Nuechterlein KH, Subotnik KL, Ventura J, Gretchen-Doorly D, Casaus LR, Luo JS, Turner L, Kurtz AS, DeTore NR: Long-acting injectable risperidone and medication adherence enhance cognition and work functioning after a first psychotic episode (abstract). Schizophr Bull 2013;39(suppl 1):S347
15. Nuechterlein KH, Ventura J, Subotnik KL, Gretchen-Doorly D, Turner L, Casaus LR, Luo JS, Medalia A, Bell MD: Broad-spectrum cognitive remediation after a first episode of schizophrenia: impact on cognition and work/school functioning (abstract). Schizophr Bull 2013;39(suppl 1):S347
16. Silverstein SM, Roché MW, Khan Z, Carson SJ, Malinovsky I, Newbill WA, Menditto AA, Wilkniss SM: Enhancing and promoting recovery in attentionally impaired people diagnosed with schizophrenia: results from a randomized controlled trial of attention shaping in a partial hospital program. Am J Psychiatr Rehabil 2014;17:272-305
17. Smith RC, Tobe RH, Boules S, Mattiuz S, Ravishankar H, Youssef M, Baranwal N, Amiaz R, Davis JM: Effects of transcranial direct current stimulation (TDCS) on cognition and symptoms in schizophrenia (abstract). Biol Psychiatry 2014;75(suppl):20S
18. Hilt DC, Lombardo I, Gawryl M, Dgetluck N, Keefe R: Optimizing treatment and signal detection with encenicline in a CIAS phase 2b study (abstract). http://www.eventscribe.com/2014/posters/SIRS/home.asp
19. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE: Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013;70:1267-1275
20. Haig G, Baker J, Robieson W, Bain E, Othman A: Efficacy and safety of ABT-126, an a7 nicotinic cholinergic agonist, in treatment of cognitive impairment associated with schizophrenia: results from a proof of concept study (abstract). http://ascpmeeting.org/wp-content/uploads/2014/05/ASCP-Poster-Abstract-Book-Online.pdf
21. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA: Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013;38:1245-1252
22. Tregellas JR, Smucny J, Harris JG, Olincy A, Maharajh K, Kronberg E, Eichman LC, Lyons E, Freedman R: Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia. Am J Psychiatry 2014;171:549-556
23. Stover EL, Brady L, Marder SR: New paradigms for treatment development. Schizophr Bull 2007;33:1093-1099